Hotgen Biotech
Chinese biotechnology company From Wikipedia, the free encyclopedia
Hotgen Biotech (short for Beijing Hotgen Biotech Co., Ltd.), often simply referred to as Hotgen,[3] is a Chinese biological technology company[4] founded in 2005. It focuses on the manufacture of in-vitro diagnostic instruments[5] and reagents.[6] In September 2019, the company was listed on the Shanghai Stock Exchange.[7] During the novel coronavirus pandemic, it specialized in making 2019-nCoV antigen diagnostic products,[8] which obtained EU CE certification.[9]
Native name | |
|---|---|
| Simplified Chinese | 热景生物 |
| Traditional Chinese | 熱景生物 |
| Company type | Public |
| SSE: 688068 | |
| Founded | 2005 |
| Founder | Changqing Lin |
| Headquarters | Beijing[1] |
| Revenue | CN¥5.369 billion (2021)[2] |
| Website | www |
Hotgen was formerly a constituent of the STAR 50 Index.[10] Headquartered in Beijing, it also established presences in foreign markets, such as the United Kingdom,[11] France,[12] and Germany.[13] The net profit of the company in 2021 exceeded 2.3 billion yuan,[14] an increase of more than sixteen times from the previous year.[15] In 2022, its RAT kits were distributed free of charge[16] by the Hong Kong Government to the public.[17] In November 2023, it attended the MEDICA Trade Fair in Düsseldorf.[18]
History
Hotgen was established by Changqing Lin in 2005.[19] In September 2019, it went public on the STAR Market,[20] with stock symbol 688068.SH.[21] In early 2021, its COVID antigen self-test kits gained market access in Germany.[22]
As of April 2021, Hotgen's market cap surpassed RMB 10 billion.[23] In March 2022, its RAT products were approved by the NMPA.[24] In November, the Hotgen COVID-19 Antigen Home Test received an EUA from the FDA.[25]
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.